Kohei Hosokawa

Kohei Hosokawa

Auto-generated profile, based on publicly available information

Kohei Hosokawa

Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa,Ishikawa, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
BDBogdan Dumitriu
Bogdan Dumitriu
KHKohei Hosokawa
Kohei Hosokawa
HMHideki Makishima
Hideki Makishima
KYKenichi Yoshida
Kenichi Yoshida
SOSeishi Ogawa
Seishi Ogawa
In patients with acquired aplastic anemia, destruction of hematopoietic cells by the immune system leads to pancytopenia. Patients have a response to immunosuppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia develop in about 15% of the patients, usually many months to years after the diagnosis of aplastic anemia. We performed next-generation sequencing and array-based karyotyping using 668 blood samples obtained from 439 patients with aplastic anemia. We analyzed serial samples obtained from 82 patients. Somatic mutations in myeloid cancer candidate genes were present in one third of the patients, in a limited number of genes and at low initial variant allele frequency. Clonal hematopoiesis was detected in 47% of the patients, most frequently as acquired mutations. The prevalence of the mutations increased with age, and mutations had an age-related signature. DNMT3A-mutated and ASXL1-mutated clones tended to increase in size over time; the size of BCOR- and BCORL1-mutated and PIGA-mutated clones decreased or remained stable. Mutations in PIGA and BCOR and BCORL1 correlated with a better response to immunosuppressive therapy and longer and a higher rate of overall and progression-free survival; mutations in a subgroup of genes that included DNMT3A and ASXL1 were associated with worse outcomes. However, clonal dynamics were highly variable and might not necessarily have predicted the response to therapy and long-term survival among individual patients. Clonal hematopoiesis was prevalent in aplastic anemia. Some mutations were related to clinical outcomes. A highly biased set of mutations is evidence of Darwinian selection in the failed bone marrow environment. The pattern of somatic clones in individual patients over time was variable and frequently unpredictable. (Funded by Grant-in-Aid for Scientific Research and others.)

15 December 2011 in Blood
Verified
Journal Article
Closed access
PDF file
TKTakamasa Katagiri
Takamasa Katagiri
ASAiko Sato-Otsubo
Aiko Sato-Otsubo
KKKoichi Kashiwase
Koichi Kashiwase
SMSatoko Morishima
Satoko Morishima
YSYusuke Sato
Yusuke Sato
OPOn Behalf Of The Japan Marrow Donor Program
On Behalf Of The Japan Marrow Donor Program
Idiopathic aplastic anemia (AA) is a common cause of acquired BM failure. Although autoimmunity to hematopoietic progenitors is thought to be responsible for its pathogenesis, little is known about the molecular basis of this autoimmunity. Here we show that a substantial proportion of AA patients harbor clonal hematopoiesis characterized by the presence of acquired copy number-neutral loss of heterozygosity (CNN-LOH) of the 6p arms (6pLOH). The 6pLOH commonly involved the HLA locus, leading to loss of one HLA haplotype. Loss of HLA-A expression from multiple lineages of leukocytes was confirmed by flow cytometry in all 6pLOH(+) cases. Surprisingly, the missing HLA-alleles in 6pLOH(+) clones were conspicuously biased to particular alleles, including HLA-A*02:01, A*02:06, A*31:01, and B*40:02. A large-scale epidemiologic study on the HLA alleles of patients with various hematologic diseases revealed that the 4 HLA alleles were over-represented in the germline of AA patients. These findings indicate that the 6pLOH(+) hematopoiesis found in AA represents “escapes” hematopoiesis from the autoimmunity, which is mediated by cytotoxic T cells that target the relevant auto-antigens presented on hematopoietic progenitors through these class I HLAs. Our results provide a novel insight into the genetic basis of the pathogenesis of AA.

15 February 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KHKohei Hosokawa
Kohei Hosokawa
PMPawel Muranski
Pawel Muranski
XFXingmin Feng
Xingmin Feng
DTDanielle M. Townsley
Danielle M. Townsley
BLBaoying Liu
Baoying Liu
NYNeal S. Young
Neal S. Young
Memory stem T cells (TSCMs) constitute a long-lived, self-renewing lymphocyte population essential for the maintenance of functional immunity. Hallmarks of autoimmune disease pathogenesis are abnormal CD4+ and CD8+ T cell activation. We investigated the TSCM subset in 55, 34, 43, and 5 patients with acquired aplastic anemia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell disease, respectively, as well as in 41 age-matched healthy controls. CD8+ TSCM frequency was significantly increased in AA compared with healthy controls. An increased CD8+ TSCM frequency at diagnosis was associated with responsiveness to immunosuppressive therapy, and an elevated CD8+ TSCM population after immunosuppressive therapy correlated with treatment failure or relapse in AA patients. IFN-γ and IL-2 production was significantly increased in various CD8+ and CD4+ T cell subsets in AA patients, including CD8+ and CD4+ TSCMs. CD8+ TSCM frequency was also increased in patients with autoimmune uveitis or sickle cell disease. A positive correlation between CD4+ and CD8+ TSCM frequencies was found in AA, autoimmune uveitis, and systemic lupus erythematosus. Evaluation of PD-1, CD160, and CD244 expression revealed that TSCMs were less exhausted compared with other types of memory T cells. Our results suggest that the CD8+ TSCM subset is a novel biomarker and a potential therapeutic target for AA.

11 June 2012 in Haematologica
Verified
Journal Article
Open access
PDF file
KHK. Hosokawa
K. Hosokawa
TKT. Katagiri
T. Katagiri
NSN. Sugimori
N. Sugimori
KIK. Ishiyama
K. Ishiyama
YSY. Sasaki
Y. Sasaki
SNS. Nakao
S. Nakao
To characterize bone marrow failure with del(13q), we reviewed clinical records of 22 bone marrow failure patients possessing del(13q) alone or del(13q) plus other abnormalities. All del(13q) patients were diagnosed with myelodysplastic syndrome-unclassified due to the absence of apparent dysplasia. Elevated glycosylphosphatidylinositol-anchored protein-deficient blood cell percentages were detected in all 16 with del(13q) alone and 3 of 6 (50%) patients with del(13q) plus other abnormalities. All 14 patients with del(13q) alone and 2 of 5 (40%) patients with del(13q) plus other abnormalities responded to immunosuppressive therapy with 10-year overall survival rates of 83% and 67%, respectively. Only 2 patients who had abnormalities in addition to the del(13q) abnormality developed acute myeloid leukemia. Given that myelodysplastic syndrome-unclassified with del(13q) is a benign bone marrow failure subset characterized by good response to immunosuppressive therapy and a high prevalence of increased glycosylphosphatidylinositol-anchored protein-deficient cells, del(13q) should not be considered an intermediate-risk chromosomal abnormality.

28 July 2011 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
KIK. Ishiyama
K. Ishiyama
TKT. Katagiri
T. Katagiri
KOK. Ohata
K. Ohata
KHK. Hosokawa
K. Hosokawa
YKY. Kondo
Y. Kondo
SNS. Nakao
S. Nakao

22 September 2016 in Haematologica
Verified
Journal Article
Open access
PDF file
KHKohei Hosokawa
Kohei Hosokawa
SKSachiko Kajigaya
Sachiko Kajigaya
XFXingmin Feng
Xingmin Feng
MDMarie J. Desierto
Marie J. Desierto
MIMaria del Pilar Fernandez Ibanez
Maria del Pilar Fernandez Ibanez
NYNeal S. Young
Neal S. Young
Aplastic anemia is an acquired bone marrow disease characterized by marrow hypoplasia, a paucity of hematopoietic stem and progenitor cells, and pancytopenia of the peripheral blood, due to immune attack on the bone marrow. In aplastic anemia, a major challenge is to develop immune biomarkers to monitor the disease. We analyzed circulating miRNAs in plasma samples of aplastic anemia patients in order to identify disease-specific miRNAs. A total of 179 miRNAs were analyzed in 35 plasma samples from 13 aplastic anemia, 11 myelodysplastic syndrome, and 11 healthy controls using the Serum/Plasma Focus microRNA PCR Panel. Subsequently, 19 miRNAs from the discovery set were investigated in the 108 plasma samples from 41 aplastic anemia, 24 myelodysplastic syndrome, and 43 healthy controls for validation, confirming that three miRNAs could be validated as dysregulated (> 1.5 fold change) in aplastic anemia, compared to healthy controls. MiR-150-5p (induction of T-cell differentiation) and miR-146b-5p (involvement in the feedback regulation of innate immune response) were elevated in aplastic anemia plasma, whereas miR-1 was decreased in aplastic anemia. By receiver-operating characteristic curve analysis, we developed a logistic model with these three miRNAs that enabled us to predict the probability of a diagnosis of aplastic anemia with an area under the curve of 0.86. Dysregulated expression levels of the miRNAs were normalized after immunosuppressive therapy at 6 months. Specifically, miR-150-5p expression was significantly reduced after successful immunosuppressive therapy, but did not change in non-responders. We propose three novel plasma biomarkers in AA, in which miR-150-5p, miR-146b-5p, and miR-1 can serve for diagnosis and miR-150-5p for disease monitoring.